News from Debiopharm Group A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Jun 07, 2016, 11:14 ET Debiopharm International SA Initiates Clinical Phase II Study Evaluating Debio 1143 in Ovarian Cancer

Debiopharm International SA (Debiopharm), part of Debiopharm Group™, a Swiss-based global biopharmaceutical company, today...


Jun 02, 2016, 03:00 ET FDA Grants Orphan Drug Designation to Debiopharm International SA's IAP Inhibitor Debio 1143 in the Treatment of Ovarian Cancer

Debiopharm International SA (Debiopharm), a Swiss-based company, part of Debiopharm Group™, today announced that the FDA Office of...


May 11, 2016, 08:00 ET Debiopharm Group™ Donates to IMD to Promote Best Practice in Family Business Philanthropy

Family businesses comprise upwards of 70% of companies worldwide and contribute extensively to the global economy and philanthropy today. However...


Mar 04, 2016, 03:00 ET Debiopharm International SA Has Won Its Patent Infringement Suit for Elplat® Against Nippon Kayaku Co., Ltd.

Debiopharm International SA (Debiopharm), part of Debiopharm Group™, a Swiss-based global biopharmaceutical company today...


Jan 13, 2016, 10:00 ET Debiopharm International SA and EORTC Announce a Collaboration to Investigate Triptorelin for Treatment of Salivary Gland Cancers

Debiopharm International SA (Debiopharm), part of Debiopharm Group™, a Swiss-based global biopharmaceutical company, today announced a...


Jan 11, 2016, 09:30 ET Debiopharm International SA and Arbor Pharmaceuticals, LLC Announce Their US Commercialization Partnership for Triptorelin in Central Precocious Puberty

Debiopharm International SA (Debiopharm), part of Debiopharm Group™, a Swiss-based global biopharmaceutical company, and...


Dec 08, 2015, 03:00 ET L'EMA accorde la Désignation de Médicament Orphelin à l'inhibiteur d'IAP Debio 1143 développé par Debiopharm International SA pour le traitement du cancer de l'ovaire

Debiopharm International SA (Debiopharm), partie intégrante de Debiopharm Group™, une société biopharmaceutique...


Dec 08, 2015, 03:00 ET EMA Grants Orphan Drug Designation to Debiopharm International SA's IAP Inhibitor Debio 1143 in the Treatment of Ovarian Cancer

Debiopharm International SA (Debiopharm), part of Debiopharm Group™, a Swiss-based global biopharmaceutical company, today...


Dec 07, 2015, 03:00 ET United Laboratories Inc. and Debiopharm International SA Announce the Launch of Pamorelin® LA in the Philippines

United Laboratories Inc. (Unilab) and Debiopharm International SA (Debiopharm) announce the signature of an exclusive agreement for...


Nov 24, 2015, 03:00 ET Debiopharm International SA's Partner Yakult Honsha Co, Ltd. Announces Elplat® Approbation in Gastric Cancer in Japan

Debiopharm International SA (Debiopharm), part of Debiopharm Group™, a Swiss-based global biopharmaceutical company, is proud...


Nov 03, 2015, 03:00 ET Debiopharm International SA Presents Positive Preliminary Results From Phase 1 Trials in the Development of the IAP Inhibitor Debio 1143 at the 27th EORTC-NCI-AACR Symposium in Boston

Debiopharm International SA (Debiopharm) - part of Debiopharm Group™, a Swiss-based global biopharmaceutical company - today...


Oct 09, 2015, 03:00 ET La Japanese Cancer Association et Debiopharm Group™ annoncent les vainqueurs du 'JCA-Mauvernay Award' 2015

Le JCA-Mauvernay Award 2015 est décerné aux Docteurs Yutaka Kondo et Junko Takita    Le 10 octobre,...


Oct 09, 2015, 03:00 ET Die Japanische Krebsgesellschaft und die Debiopharm Group geben die Gewinner des JCA-Mauvernay Awards 2015 bekannt

Der "JCA-Mauvernay Award 2015" geht an Dr. Yutaka Kondo und Dr. Junko Takita   Die Debiopharm Group™, das weltweit...


Oct 09, 2015, 03:00 ET La Japanese Cancer Association y Debiopharm Group anuncian a los ganadores del 2015 JCA-Mauvernay Award

El 'JCA-Mauvernay Award 2015' se ha otorgado a los doctores Yutaka Kondo y Junko Takita   Debiopharm Group™, una...


Sep 08, 2015, 03:00 ET Debiopharm International SA und Solid Biosciences, LLC, kündigen Partnerschaft an, um die Anwendung von Alisporivir (Debio 025) bei Muskeldystrophie zu erforschen

Debiopharm startet zusammen mit Solid Biosciences, einem auf DMD spezialisiertes Biotech-Unternehmen, präklinische Tierstudien für...


Sep 08, 2015, 03:00 ET Debiopharm International SA et Solid Biosciences, LLC débutent une collaboration afin d' explorer l'utilisation de l'Alisporivir (Debio 025) dans le traitement de la dystrophie musculaire

Debiopharm initiera des études précliniques pour le traitement de la myopathie de Duchenne (MD) sur des modèles animaux   en...


Sep 08, 2015, 03:00 ET Debiopharm International SA y Solid Biosciences, LLC explorarán el uso de Alisporivir

- Debiopharm International SA y Solid Biosciences, LLC anuncian una colaboración para explorar el uso de Alisporivir (Debio 025) en la...


Sep 08, 2015, 03:00 ET Debiopharm International SA and Solid Biosciences, LLC, Announce a Collaboration to Explore the Use of Alisporivir (Debio 025) in Muscular Dystrophy

Debiopharm to start pre-clinical animal studies in Duchenne Muscular Dystrophy (DMD) with Solid Biosciences, a DMD-focused biotech...


Jan 13, 2015, 10:00 ET Debiopharm Diagnostics mène un tour d'investissement dans la société GenePOC avec Emerillon Capital

GenePOC est une société canadienne qui a développé une plateforme de diagnostics moléculaires (MDx) rapide, innovante et...


Jan 13, 2015, 10:00 ET Debiopharm Diagnostics Leads Investment Round in GenePOC With Emerillon Capital

Debiopharm Diagnostics, part of Debiopharm Group™, is proud to be the lead investor in GenePOC, which is developing a highly...


Jan 12, 2015, 02:30 ET Debiopharm Group™ récupère les droits complets du programme sur l'Alisporivir

- Novartis restitue l'Alisporivir (DEB025) à Debiopharm Group™ , y compris tous les droits pour le virus de l'hépatite C et...


Jan 12, 2015, 02:30 ET Debiopharm Group™ Regains Full Rights to Alisporivir Program

Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical company, today announced that it has updated its arrangement...


Jan 08, 2015, 03:00 ET FDA Grants Fast Track Designation to Debiopharm Group's Antibiotic Debio 1450

Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical company, today announced that the US...


Jan 08, 2015, 03:00 ET La FDA accorde la désignation Fast Track à l'antibiotique Debio 1450 de Debiopharm Group

- Le Debio 1450, un inhibiteur de FabI administré par voie orale/IV actif contre toutes les espèces de staphylocoques, a reçu la...


Nov 18, 2014, 07:00 ET Debiopharm Group™ Presents Advances of two key Oncology Clinical Programs at the 26th EORTC-NCI-AACR Symposium in Barcelona

Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical company developing prescription drugs along with companion...